No treatment here: scientists Double-Check their own lab methods
NCT ID NCT07083557
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is not testing a new drug or treatment. Instead, researchers want to make sure their lab tests and equipment give accurate and repeatable results when studying conditions like obesity, diabetes, heart disease, and bone loss. Up to 100 healthy volunteers and people with these conditions will provide blood, urine, tissue samples, or undergo imaging to help validate these methods. The goal is to improve the quality of future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
convenience population of volunteers in mid-Missouri region
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥18 and ≤100 years of age * body mass index ≥16.0 and ≤60 kg/m2 Exclusion Criteria: * \<18 and \>100 years of age * body mass index \<16.0 or \>60 kg/m2 * allergies, intolerances, or dietary restrictions to meal ingredients, vegans or vegetarians * use of medications or dietary supplements (e.g., anti-inflammatories, immune modulators, etc) that could interfere with the particular assay/techniques being evaluated * engaged in regular structured exercise \>150 min per week unless needed for validation of the assay/technique being evaluated * significant organ system dysfunction or diseases, except those that are sought for validation of the assay/technique being evaluated * alcohol use disorder as defined by the National Institute of Alcohol Abuse and Alcoholism or use of controlled substances unless alcohol use disorder is required for validation of the assay/technique being evaluated * pregnant women, persons who smoke, prisoners, and inability to grant voluntary informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerotic disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Missouri-Columbia
RECRUITINGColumbia, Missouri, 65211, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic effects of switching from injectable semaglutide to tirzepatide: a retrospective study of the LMC diabetes registry
- Rural community peer partnerships for improving Methamphetamine-Associated heart failure screening and engagement
- An open-label extension (OLE) Sub-Study subsequent to the phase 2/3 randomized, Double-Blind study of rilogrotug versus placebo in the treatment of weight loss and anorexia in patients with cancer cachexia and mCRC or mNSCLC
- Agreement of the estimated 1-Repetition-Maximum between two Multiple-Repetition-Maximum tests with different weight in patients with cardiovascular disease or risk factors
- A randomized, open-label, controlled, multiple dose, safety, pharmacokinetic, and pharmacodynamic study of PLS240 in pediatric participants 1 month to <18 years of age with secondary hyperparathyroidism and chronic kidney disease receiving maintenance hemodialysis
- Assessing the efficacy of melatonin and osteogenic loading on bone health in an osteopenic population: MelaOstrong study